Original Articles

Comparison of Cutaneous Leishmaniasis Patients in One-Year Pre-Outbreak and One-Year Post-Outbreak of COVID-19 in Shiraz City, Iran

Abstract

Iran ranks among the top ten countries for leishmaniasis and COVID-19 outbreaks. This study compared cutaneous leishmaniasis (CL) cases in Shiraz one year before and one year after the COVID-19 outbreak. In this study, the recorded information of 988 suspected cutaneous leishmaniasis (CL) patients referred to Valfajr Health Center was meticulously collected, prepared, and analyzed using the SPSS-24 Software and the Chi-square test. Comparing the pre-outbreak period (February 2019-March 2020) to the post-outbreak period (March 2021), 57.9% of 526 suspected CL cases were positive before the outbreak versus 76.4% of 462 cases after the outbreak. Pre-outbreak, women constituted 53.8% of CL cases, whereas post-outbreak, men constituted 55.8% of cases. The presence of underlying conditions, notably diabetes and hypertension, increased 3.5 times after the COVID-19 outbreak. Employment status also shifted, with increases in employed (from 5.3% to 10.5%) and self-employed (from 44.4% to 47.7%) individuals and a decrease in housewives (from 48.3% to 37.6%). COVID-19 has significantly impacted CL parameters, particularly gender distribution, employment status, and the acute-chronic nature of the disease, due to increased economic activity and community presence.

1. Al-Salem WS, Pigott DM, Subramaniam K, Haines LR, Kelly-Hope L, Molyneux DH, et al. Cutaneous leishmaniasis and conflict in Syria. Emerg Infect Dis 2016;22:931.
2. Saki J, Tavakoli S, Mardani M, Salmanzadeh S, Karamkhani A. A 5-year period (2010–2014) retrospective study of human cutaneous leishmaniasis in Ahvaz County, southwest of Iran. Asian Pac J Trop Dis 2016;6:429-31.
3. Zijlstra EE. PKDL and other dermal lesions in HIV co-infected patients with leishmaniasis: review of clinical presentation in relation to immune responses. PLoS Negl Trop Dis 2014;8:e3258.
4. Hajjaran H, Mohebali M, Razavi MR, Rezaei S, Kazemi B, Edrissian G, et al. Identification of Leishmania species isolated from human cutaneous leishmaniasis, using random amplified polymorphic DNA (RAPD-PCR). Iran J Public Health 2004; 33:8-15.
5. Yektaeian N, Zare S, Radfar AH, Hatam G. Superparamagnetic Iron Oxide‐Labeled Leishmania major Can Be Traced in Fibroblasts. J Parasitol Res 2023;2023:7628912.
6. Farash BR, Mohajery M, Fata A, Shamsian SA, Rezaee A, Yazdanpanah MJ. Anthroponotic cutaneous leishmaniasis in torghabeh-shandiz, a region with rural texture (a molecular study). Jundishapur J Microbiol 2013;6.
7. Anderson RM, Fraser C, Ghani AC, Donnelly CA, Riley S, Ferguson NM, et al. Epidemiology, transmission dynamics and control of SARS: the 2002–2003 epidemic. Philos Trans R Soc Lond B Biol Sci 2004;359:1091-105.
8. Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int J Epidemiol 2020;49:717-26.
9. Hsieh YH, Lee JY, Chang HL. SARS epidemiology modeling. Emerg Infect Dis 2004;10:1165-7.
10. Zhou G, Yan G. Severe acute respiratory syndrome epidemic in Asia. Emerg Infect Dis 2003;9:1608-10.
11. Mobaraki K, Ahmadzadeh J. Current epidemiological status of Middle East respiratory syndrome coronavirus in the World From 112017 To 1712018: A Cross-Sectional Study. BMC Infect Dis 2019;19:351.
12. Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, Lu GM, et al. Coronavirus Disease 2019 (COVID-19): A Perspective from China. Radiology 2020;296:E15-E25.
13. Pourfarzi F, Rahim Pouran S, Dargahi A, Karami C, Fouladi N, Zandian H, et al. The healthy behaviours and COVID-19 mortality among Iranian women: a case–control study. BMC Womens Health 2021;21:281.
14. Le Rutte EA, Coffeng LE, Muñoz J, De Vlas SJ. Modelling the impact of COVID-19-related programme interruptions on visceral leishmaniasis in India. Trans R Soc Trop Med Hyg 2021;115:229-35.
15. Miguel DC, Brioschi MB, Rosa LB, Minori K, Grazzia N. The impact of COVID-19 on neglected parasitic diseases: what to expect?. Trends Parasitol 2021;37:694-7.
16. Hollingsworth TD, Mwinzi P, Vasconcelos A, De Vlas SJ. Evaluating the potential impact of interruptions to neglected tropical disease programmes due to COVID-19. Trans R Soc Trop Med Hyg 2021;115:201-4.
17. Ansumana R, Sankoh O, Zumla A. Effects of disruption from COVID-19 on antimalarial strategies. Nat Med 2020;26:1334-6.
18. Sherrard-Smith E, Hogan AB, Hamlet A, Watson OJ, Whittaker C, Winskill P, et al. The potential public health consequences of COVID-19 on malaria in Africa. Nat Med 2020;26:1411-6.
19. Cilloni L, Fu H, Vesga JF, Dowdy D, Pretorius C, Ahmedov S, et al. The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis. EClinicalMedicine 2020;28:100603.
20. Chanda-Kapata P, Ntoumi F, Kapata N, Lungu P, Mucheleng’anga LA, Chakaya J, et al. Tuberculosis, HIV/AIDS and malaria health services in sub-Saharan Africa–a situation analysis of the disruptions and impact of the COVID-19 pandemic. Int J Infect Dis 2022;124:41-6.
21. Mazaherifar S, Solhjoo K, Abdoli A. Outbreak of cutaneous leishmaniasis before and during the COVID-19 pandemic in Jahrom, an endemic region in the southwest of Iran. Emerg Microbes Infect 2022;11:2218-21.
Files
IssueVol 64 No 8 (2026) QRcode
SectionOriginal Articles
Keywords
COVID-19 Cutaneous leishmaniasis Iran Outbreak
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Yektaeian N, Saheli AA, Dousti M, Ķhatamifar V, Shirani M, Hatam G. Comparison of Cutaneous Leishmaniasis Patients in One-Year Pre-Outbreak and One-Year Post-Outbreak of COVID-19 in Shiraz City, Iran. Acta Med Iran. 2026;64(8):477-481.